Dietary supplementation with Bifidobacterium longum subsp. infantis (B. infantis) in healthy breastfed infants: Study protocol for a randomised controlled trial

Smita Awasthi, Reason Wilken, Forum Patel, J. Bruce German, David A. Mills, Carlito B. Lebrilla, Kyoungmi Kim, Samara L. Freeman, Jennifer T. Smilowitz, April W Armstrong, Emanual Maverakis

Research output: Contribution to journalArticlepeer-review

5 Scopus citations

Abstract

Background: The development of probiotics as therapies to cure or prevent disease lags far behind that of other investigational medications. Rigorously designed phase I clinical trials are nearly non-existent in the field of probiotic research, which is a contributing factor to this disparity. As a consequence, how to appropriately dose probiotics to study their efficacy is unknown. Herein we propose a novel phase I ascending dose trial of Bifidobacterium longum subsp. infantis (B. infantis) to identify the dose required to produce predominant gut colonisation in healthy breastfed infants at 6 weeks of age. Methods/design: This is a parallel-group, placebo-controlled, randomised, double-blind ascending dose phase I clinical trial of dietary supplementation with B. infantis in healthy breastfed infants. The objective is to determine the pharmacologically effective dose (ED) of B. infantis required to produce predominant (>50 %) gut colonisation in breastfed infants at 6 weeks of age. Successively enrolled infant groups will be randomised to receive two doses of either B. infantis or placebo on days 7 and 14 of life. Stool samples will be used to characterise the gut microbiota at increasing doses of B. infantis. Discussion: Probiotic supplementation has shown promising results for the treatment of a variety of ailments, but evidence-based dosing regimes are currently lacking. The ultimate goal of this trial is to establish a recommended starting dose of B. infantis for further efficacy-testing phase II trials designed to evaluate B. infantis for the prevention of atopic dermatitis and food allergies in at-risk children. Trial registration: Clinicaltrials.gov #NCT02286999 , date of trial registration 23 October 2014.

Original languageEnglish (US)
Article number340
JournalTrials
Volume17
Issue number1
DOIs
StatePublished - Jul 22 2016

Keywords

  • Atopic dermatitis
  • Atopy
  • Bifidobacterium infantis
  • Dose-escalation
  • Food allergy
  • Phase I clinical trial
  • Probiotic

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Dietary supplementation with Bifidobacterium longum subsp. infantis (B. infantis) in healthy breastfed infants: Study protocol for a randomised controlled trial'. Together they form a unique fingerprint.

Cite this